{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:09:03Z","timestamp":1789790943377,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To compare the efficacy and safety of half-dose and one-third-dose photodynamic therapy (PDT) with verteporfin in patients with chronic central serous chorioretinopathy (CSC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study included 72 eyes from 72 patients with chronic CSC treated with either one-third-dose (2\u00a0mg\/m\u00b2) or half-dose (3\u00a0mg\/m\u00b2) PDT. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), subretinal fluid (SRF) thickness, subfoveal choroidal thickness (SFCT), and optical coherence tomography (OCT) features were evaluated at baseline, 3 months, and 12 months. Fluorescein angiography (FA) was used to guide laser application. Treatment outcomes, including SRF resolution, BCVA gain, and recurrence rates, were compared between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At 12 months, complete SRF resolution was achieved in 40 eyes (78.4%) in the half-dose group and 15 eyes (71.4%) in the one-third-dose group. The recurrence rate of SRF was significantly higher in the one-third-dose group (20%) compared to the half-dose group (7.5%) (<jats:italic>P<\/jats:italic>\u2009=.015). BCVA improved significantly in both groups, with mean increases from 72.4\u2009\u00b1\u20093.9 to 77.1\u2009\u00b1\u20095.6 letters in the one-third-dose group and from 74.4\u2009\u00b1\u20094.2 to 80.2\u2009\u00b1\u20092.19 letters in the half-dose group. The proportion of patients achieving a\u2009\u2265\u200910-letter gain was higher in the half-dose group (52%) compared to the one-third-dose group (28.5%, <jats:italic>P<\/jats:italic>\u2009=.001). Both groups exhibited significant reductions in CRT, SRF thickness, and SFCT (<jats:italic>P<\/jats:italic>\u2009&lt;.001), with no significant intergroup differences. Baseline CRT and fluorescein leakage patterns influenced treatment response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Both one-third-dose and half-dose PDT effectively improved visual and anatomical outcomes in patients with chronic CSC. However, half-dose PDT demonstrated superior efficacy in achieving SRF resolution and greater visual acuity gains with a lower recurrence rate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40942-025-00657-6","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T14:47:56Z","timestamp":1742309276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy of half-dose and one-third-dose photodynamic therapy in chronic central serous chorioretinopathy: a retrospective study"],"prefix":"10.1186","volume":"11","author":[{"given":"Mohsen","family":"Farvardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorna","family":"Eghtedari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shahmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadkarim","family":"Johari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"657_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00006982-198700720-00009","volume":"7","author":"LA Yannuzzi","year":"1987","unstructured":"Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina. 1987;7:111\u201331. https:\/\/doi.org\/10.1097\/00006982-198700720-00009.","journal-title":"Retina"},{"key":"657_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","volume":"58","author":"B Nicholson","year":"2013","unstructured":"Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58:103\u201326.","journal-title":"Surv Ophthalmol"},{"key":"657_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","volume":"22","author":"RH Loo","year":"2002","unstructured":"Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19\u201324. https:\/\/doi.org\/10.1097\/00006982-200202000-00004.","journal-title":"Retina"},{"key":"657_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/jamaophthalmol.2014.5312","volume":"133","author":"M Zhao","year":"2015","unstructured":"Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, et al. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133:333\u201340. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.5312.","journal-title":"JAMA Ophthalmol"},{"key":"657_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3928\/1542-8877-19970801-16","volume":"28","author":"PK Khosla","year":"1997","unstructured":"Khosla PK, Rana SS, Tewari HK, Azad RU, Talwar D. Evaluation of visual function following argon laser photocoagulation in central serous retinopathy. Ophthalmic Surg Lasers. 1997;28:693\u20137.","journal-title":"Ophthalmic Surg Lasers"},{"key":"657_CR6","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41433-019-0692-8","volume":"34","author":"Z Sun","year":"2020","unstructured":"Sun Z, Huang Y, Nie C, et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. Eye. 2020;34:1592\u20139. https:\/\/doi.org\/10.1038\/s41433-019-0692-8.","journal-title":"Eye"},{"issue":"3","key":"657_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/00006982-200306000-00002","volume":"23","author":"LA Yannuzzi","year":"2003","unstructured":"Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288\u201398.","journal-title":"Retina"},{"issue":"6","key":"657_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/00006982-200312000-00002","volume":"23","author":"F Cardillo Piccolino","year":"2003","unstructured":"Cardillo Piccolino F, Eandi CM, Ventre L, de la Rigault RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23(6):752\u201363.","journal-title":"Retina"},{"issue":"2","key":"657_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00006982-200602000-00027","volume":"26","author":"M Colucciello","year":"2006","unstructured":"Colucciello M. Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina. 2006;26(2):239\u201342.","journal-title":"Retina"},{"issue":"10","key":"657_CR10","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","volume":"115","author":"WM Chan","year":"2008","unstructured":"Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115(10):1756\u201365.","journal-title":"Ophthalmology"},{"issue":"4","key":"657_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1097\/IAE.0b013e3181f049d3","volume":"31","author":"K Fujita","year":"2011","unstructured":"Fujita K, Yuzawa M, Mori R. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Retina. 2011;31(4):772\u20138.","journal-title":"Retina"},{"issue":"8","key":"657_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/IAE.0b013e3181a6c028","volume":"29","author":"MW Zhao","year":"2009","unstructured":"Zhao MW, Zhou P, Xiao HX, et al. Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina. 2009;29(8):1155\u201361.","journal-title":"Retina"},{"issue":"9","key":"657_CR13","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1097\/IAE.0b013e3182252aa8","volume":"31","author":"A Shinojima","year":"2011","unstructured":"Shinojima A, Kawamura A, Mori R, Fujita K, Yuzawa M. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy. Retina. 2011;31(9):1912\u201320.","journal-title":"Retina"},{"issue":"3","key":"657_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/jamaophthalmol.2014.5312","volume":"133","author":"M Zhao","year":"2015","unstructured":"Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, et al. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133(3):333\u201340.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"657_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12886-020-01761-8","volume":"21","author":"J Pichai","year":"2021","unstructured":"Pichai J, Vanchalerm B, Mansing R. One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy. BMC Ophthalmol. 2021;21(1):30. https:\/\/doi.org\/10.1186\/s12886-020-01761-8.","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"657_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/eye.2012.66","volume":"26","author":"R Uetani","year":"2012","unstructured":"Uetani R, Ito Y, Oiwa K, Ishikawa K, Terasaki H. Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy. Eye (Lond). 2012;26(5):640\u20139.","journal-title":"Eye (Lond)"},{"key":"657_CR17","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s40123-024-00952-9","volume":"13","author":"MJ Sirks","year":"2024","unstructured":"Sirks MJ, Subhi Y, Rosenberg N, et al. Perspectives and update on the global shortage of verteporfin (Visudyne\u00ae). Ophthalmol Ther. 2024;13:1821\u201331. https:\/\/doi.org\/10.1007\/s40123-024-00952-9.","journal-title":"Ophthalmol Ther"},{"key":"657_CR18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ajo.2004.01.043","volume":"137","author":"M Taban","year":"2004","unstructured":"Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol. 2004;137:1073\u201380.","journal-title":"Am J Ophthalmol"},{"key":"657_CR19","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.ophtha.2005.06.026","volume":"112","author":"MD Ober","year":"2005","unstructured":"Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology. 2005;112:2088\u201394.","journal-title":"Ophthalmology"},{"issue":"10","key":"657_CR20","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00417-009-1104-8","volume":"247","author":"JW Moon","year":"2009","unstructured":"Moon JW, Yu HG, Kim TW, Kim HC, Chung H. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):1315\u201323.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"657_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ajo.2004.08.037","volume":"139","author":"FC Piccolino","year":"2005","unstructured":"Piccolino FC, de la Longrais RR, Ravera G, et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol. 2005;139(1):87\u201399.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"657_CR22","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00417-013-2270-2","volume":"251","author":"H Vasconcelos","year":"2013","unstructured":"Vasconcelos H, Marques I, Santos AR, et al. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1697\u2013705. https:\/\/doi.org\/10.1007\/s00417-013-2270-2.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"657_CR23","doi-asserted-by":"publisher","first-page":"102081","DOI":"10.1016\/j.pdpdt.2020.102081","volume":"33","author":"MG Altinel","year":"2021","unstructured":"Altinel MG, Kanra AY, Totuk OMG, Ardagil A, Kabadayi K. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy. Photodiagnosis Photodyn Ther. 2021;33:102081. https:\/\/doi.org\/10.1016\/j.pdpdt.2020.102081.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"657_CR24","doi-asserted-by":"publisher","first-page":"101236","DOI":"10.1016\/j.preteyeres.2024.101236","volume":"101","author":"HMA Feenstra","year":"2024","unstructured":"Feenstra HMA, van Dijk EHC, Cheung CMG, Ohno-Matsui K, Lai TYY, Koizumi H, Larsen M, Querques G, Downes SM, Yzer S, Breazzano MP, Subhi Y, Tadayoni R, Priglinger SG, Pauleikhoff LJB, Lange CAK, Loewenstein A, Diederen RMH, Schlingemann RO, Hoyng CB, Chhablani JK, Holz FG, Sivaprasad S, Lotery AJ, Yannuzzi LA, Freund KB, Boon CJF. Central serous chorioretinopathy: an evidence-based treatment guideline. Prog Retin Eye Res. 2024;101:101236. https:\/\/doi.org\/10.1016\/j.preteyeres.2024.101236.","journal-title":"Prog Retin Eye Res"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00657-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T14:47:58Z","timestamp":1742309278000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00657-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00657-6","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol used in this study was approved by the Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.MED.REC.1403.494), All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki) the requirement for informed patient consent was waived due to the study\u2019s retrospective design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}